Article · 13 Feb 2026
Conference abstractPublished 21 Oct 2013
The relevance of safe final destination and rational prescription of drugs under regulatory issues with inclusion of environmental impact analysis on pharmacoeconomics studies
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The final destination of medicine residues is a relevant subject to the public health due to the pharmacological properties of each medicine and inputs, that in future will become a residue and will need to be treated. We don?t have specific guidelines for medicines classification and pharmaceutical waste. A range of methodologies are available for pharmacoeconomics evaluation but they didn?t incorporate adverse environmental effects causing physiological disturbances for humans and animals. The industrial segment follows different regulations that are formulated for industry in general. Thus the way done by drugs and inputs generated from manufacturing to the use by the end user fragments in the legislation because the process of classification to the final destination are not clearly defined. The goal of this monograph is propose to the Official Regulatory Agency create guidelines for the development of a classification system specifically for pharmaceutical waste to support the choice for drugs with pose little risk to environment and health in cases where several comparable therapeutically-equivalent, safety and costs are available. The inclusion of environmental impact data about pharmaceuticals in such selection process maybe a tool to stimulate drug manufactures to design pharmaceutical products that are less persistent after excretion, ?green? technology to production, standardization and acquisition of these kind of drugs and other proactive actions in order to minimizing the introduction of pharmaceutical residues to the environment.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Nubia Regina de Oliveira”
